Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance:first report from the prospective Lynch syndrome database

Møller, Pål and Seppälä, Toni and Bernstein, Inge and Holinski-Feder, Elke and Sala, Paola and Evans, D. Gareth and Lindblom, Annika and Macrae, Finlay and Blanco, Ignacio and Sijmons, Rolf and Jeffries, Jacqueline and Vasen, Hans and Burn, John and Nakken, Sigve and Hovig, Eivind and Rødland, Einar Andreas and Tharmaratnam, Kukatharmini and de Vos Tot Nederveen Cappel, Wouter H. and Hill, James and Wijnen, Juul and Green, Kate and Lalloo, Fiona and Sunde, Lone and Mints, Miriam and Bertario, Lucio and Pineda, Marta and Navarro, Matilde and Morak, Monika and Renkonen-Sinisalo, Laura and Frayling, Ian M. and Plazzer, John-Paul and Pylvanainen, Kirsi and Sampson, Julian R. and Capella, Gabriel and Mecklin, Jukka-Pekka and Möslein, Gabriela and , Mallorca Group (http://mallorca-group.eu) (2017) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance:first report from the prospective Lynch syndrome database. Gut, 66 (3). pp. 464-472. ISSN 0017-5749

[img]
Preview
PDF (Cancer incidence and survival in Lynch syndrome-Gut-2015-Møller-gutjnl-2015-309675)
Cancer_incidence_and_survival_in_Lynch_syndrome_Gut_2015_M_ller_gutjnl_2015_309675.pdf - Accepted Version
Available under License Creative Commons Attribution.

Download (477kB)

Abstract

OBJECTIVE: Estimates of cancer risk and the effects of surveillance in Lynch syndrome have been subject to bias, partly through reliance on retrospective studies. We sought to establish more robust estimates in patients undergoing prospective cancer surveillance. DESIGN: We undertook a multicentre study of patients carrying Lynch syndrome-associated mutations affecting MLH1, MSH2, MSH6 or PMS2. Standardised information on surveillance, cancers and outcomes were collated in an Oracle relational database and analysed by age, sex and mutated gene. RESULTS: 1942 mutation carriers without previous cancer had follow-up including colonoscopic surveillance for 13 782 observation years. 314 patients developed cancer, mostly colorectal (n=151), endometrial (n=72) and ovarian (n=19). Cancers were detected from 25 years onwards in MLH1 and MSH2 mutation carriers, and from about 40 years in MSH6 and PMS2 carriers. Among first cancer detected in each patient the colorectal cancer cumulative incidences at 70 years by gene were 46%, 35%, 20% and 10% for MLH1, MSH2, MSH6 and PMS2 mutation carriers, respectively. The equivalent cumulative incidences for endometrial cancer were 34%, 51%, 49% and 24%; and for ovarian cancer 11%, 15%, 0% and 0%. Ten-year crude survival was 87% after any cancer, 91% if the first cancer was colorectal, 98% if endometrial and 89% if ovarian. CONCLUSIONS: The four Lynch syndrome-associated genes had different penetrance and expression. Colorectal cancer occurred frequently despite colonoscopic surveillance but resulted in few deaths. Using our data, a website has been established at http://LScarisk.org enabling calculation of cumulative cancer risks as an aid to genetic counselling in Lynch syndrome.

Item Type:
Journal Article
Journal or Publication Title:
Gut
Additional Information:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Uncontrolled Keywords:
/dk/atira/pure/subjectarea/asjc/2700/2715
Subjects:
ID Code:
78245
Deposited By:
Deposited On:
03 Jun 2016 10:21
Refereed?:
Yes
Published?:
Published
Last Modified:
08 Apr 2020 03:06